4.5 Editorial Material

Real-world effectiveness and safety of baricitinib in Japanese patients with atopic dermatitis: A single-center retrospective study

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Dermatology

Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders An Extension Study of 2 Randomized Clinical Trials

Jonathan I. Silverberg et al.

Summary: Baricitinib, a selective Janus kinase inhibitor, showed sustained long-term efficacy for patients with moderate to severe atopic dermatitis through 52 weeks of continuous therapy, improving clinical assessment scores and itch symptoms.

JAMA DERMATOLOGY (2021)